Regulation of PKR-dependent RNA translation inhibition by TRIM21 upon virus infection or other stress

PLoS Pathog. 2023 Jun 16;19(6):e1011443. doi: 10.1371/journal.ppat.1011443. eCollection 2023 Jun.

Abstract

The host always employs various ways to defend against viral infection and spread. However, viruses have evolved their own effective strategies, such as inhibition of RNA translation of the antiviral effectors, to destroy the host's defense barriers. Protein synthesis, commonly controlled by the α-subunit of eukaryotic translation initiation factor 2 (eIF2α), is a basic cellular biological process among all species. In response to viral infection, in addition to inducing the transcription of antiviral cytokines by innate immunity, infected cells also inhibit the RNA translation of antiviral factors by activating the protein kinase R (PKR)-eIF2α signaling pathway. Regulation of innate immunity has been well studied; however, regulation of the PKR-eIF2α signaling pathway remains unclear. In this study, we found that the E3 ligase TRIM21 negatively regulates the PKR-eIF2α signaling pathway. Mechanistically, TRIM21 interacts with the PKR phosphatase PP1α and promotes K6-linked polyubiquitination of PP1α. Ubiquitinated PP1α augments its interaction with PKR, causing PKR dephosphorylation and subsequent translational inhibition release. Furthermore, TRIM21 can constitutively restrict viral infection by reversing PKR-dependent translational inhibition of various previously known and unknown antiviral factors. Our study highlights a previously undiscovered role of TRIM21 in regulating translation, which will provide new insights into the host antiviral response and novel targets for the treatment of translation-associated diseases in the clinic.

MeSH terms

  • Antiviral Agents
  • Eukaryotic Initiation Factor-2 / genetics
  • Eukaryotic Initiation Factor-2 / metabolism
  • Humans
  • Phosphorylation
  • Protein Processing, Post-Translational
  • RNA* / metabolism
  • Virus Diseases*
  • Virus Replication
  • eIF-2 Kinase / metabolism

Substances

  • RNA
  • eIF-2 Kinase
  • Antiviral Agents
  • Eukaryotic Initiation Factor-2

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (81730064, 82072269, 81571985 and 81902069), National Major Science and Technology Projects of China (2017ZX10202201-005 and 2009ZX10004-312), Postdoctoral Research Foundation of China (2019M652760) and Hunan Provincial Innovation Foundation For Postgraduate (CX20210395). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.